22 results
Thumbnail

D1.54 - Latex-Induced Occupational Asthma: An Underrecognized Hazard in the Electronics and Cable Industry

Thumbnail

D1.46 - Molecular patterns of fungal sensitization in patients with asthma and allergic rhinitis: evidence from real-life clinical practice

Thumbnail

D1.47 - Assessment of Asthma Control in Elderly Patients Using Forced Oscillation Technique, Spirometry, and Asthma Control Test in Relation to GINA Classification

Thumbnail

D1.49 - Component-Resolved Pet Allergen Sensitization Identifies Adolescents With Airway Inflammation and Bronchial Hyperresponsiveness

Thumbnail

D1.55 - Monosensitization to Der p 23 in house dust mite allergy in daily clinical practice in a county of Gipuzkoa, Basque Country, Spain: a retrospective and descriptive analysis

Thumbnail

D1.60 - Clinical Characteristics of Children with Patch Test–Positive Allergic Contact Dermatitis: Effects of Treatment on Quality of Life

Thumbnail

D1.372 - Transition to SCIG as an Alternative in Patients with Cytokine Storm from IVIG

Thumbnail

D1.374 - Genetic susceptibility to radiocontrast media-induced anaphylaxis: A microarray gene chip study in a Korean population

Thumbnail

D1.365 - Long-term course of NSAID tolerance in patients with cross-hypersensitivity presenting with respiratory symptoms

Thumbnail

D1.367 - Risk factors for immediate hypersensitivity reactions to rituximab

Thumbnail

D1.373 - Hypersensitivity to Biologic Therapies: Mechanism of Cross-reactivity

Thumbnail

D1.376 - Successful Desensitization with Temozolomide in a Patient with a Hypersensitivity Reaction to Temozolomide

Thumbnail

D1.377 - Folic Acid Allergy: A Rare Case

Thumbnail

D1.378 - Hypersensitivity During Continuous 5-Fluorouracil Infusion: Two Cases Successfully Managed With Desensitization

Thumbnail

D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)

Thumbnail

D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety

Thumbnail

D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A

Thumbnail

D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody

Thumbnail

D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria

Thumbnail

D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis